✦ LIBER ✦

Daily oral cyclophosphamide for patients with small cell lung cancer (SCLC) unsuitable for standard treatment. A phase I/II study

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A simple outpatient treatment with oral

📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 157 KB

A simple outpatient treatment with oral

✍ Cerny, T; Lind, M; Thatcher, N; Swindell, R; Stout, R 📂 Article 📅 1989 🏛 Nature Publishing Group 🌐 English ⚖ 651 KB

Single agent oral topotecan (OT) as firs

✍ Eckardt, J.R; Palmer, M.C; Fanucchi, M.P; Gralla, R; Martins, H; Poulin, R; Fiel 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Phase II study of paclitaxel as first li

✍ Langley, R.E.; Woll, P.J.; Davidson, N.; Libretti, V.; Smyth, J.F.; Schipper, R; 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 212 KB

130 Phase II trial of carboplatin (CBDCA

✍ Kobayashi, M.; Matsui, K.; Masuda, N.; Yana, T.; Hirashima, T.; Komiya, T.; Kawa 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 151 KB

Paclitaxel and gemcitabine for refractor

✍ M. Domine; J. Gonzalez Larriba; R. Garcia Gomez; S. Morales; D. Isla; C. Garcia 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 339 KB